Related Experiment Video
Updated: Jun 23, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars and follow-on biologics.
1Widener University, One University Place, Chester, PA 19013, USA. jpfuhr@widener.edu
Summary
The 2nd Annual Summit on Biosimilars convened experts to discuss the legal, regulatory, and economic factors shaping the biosimilar market, preparing for anticipated US legislation. Future discussions will delve into pending biosimilar bills and potential new laws.
Area of Science:
- Biopharmaceuticals
- Healthcare Policy
- Regulatory Science
Background:
- The 2nd Annual Summit on Biosimilars gathered diverse stakeholders including industry, government, academics, and professionals.
- The summit addressed the complex landscape of biosimilars, encompassing legal, regulatory, and economic considerations.
- Participants focused on preparing for upcoming US legislation designed to facilitate biosimilar market entry.
Framework:
- The summit facilitated a dialogue to evaluate the current global legal and regulatory environment for biosimilars.
- Economic factors influencing biosimilar adoption and market access were critically examined.
- The event served as a platform to anticipate and strategize for the impact of new US biosimilar legislation.
Implementation:
- The summit's discussions aimed to inform strategies for navigating the evolving biosimilar market.
- Key stakeholders collaborated to understand and prepare for the implementation of new regulatory pathways.
- The exchange of knowledge prepared participants for the anticipated changes in the US biosimilar landscape.
Implications:
- The summit highlighted the critical need for a clear legal and regulatory framework to foster biosimilar competition.
- Understanding the economic implications is crucial for maximizing the benefits of biosimilars for patients and healthcare systems.
- The discussions underscored the importance of proactive engagement with policy development to ensure successful biosimilar integration.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...